Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

You may not qualify if:

• The patient has persistent clinically significant non-hematologic toxicities \>= grade 2 (excluding alopecia, nausea, and fatigue)
• Evidence of central nervous system (CNS) involvement
• Uncontrolled and active pulmonary disease
• Requirement for oxygen treatment
• Receiving chemotherapy, radiotherapy or other anti-cancer therapy within 14 days of first dose of study drug. There must be at least a 6-week interval from the last immunotherapy therapy
• Uncontrolled infection
• Human immunodeficiency virus (HIV)/hepatitis B and/or C
• Any history of invasive malignancy in the last 2 years excluding any malignancy such as cervical cancer or skin cancer (excluding melanoma) that is considered cured at the time of screening
• Pregnant or breast-feeding woman
• Patient has uncontrolled intercurrent illness or medical/psychiatric condition that would limit compliance with study requirements or that would in the investigator's opinion place the patient at an unacceptably high risk for toxicities
• Clinical significant cardiopulmonary disease including uncontrolled or New York Heart Association (NYHA) class 3 or 4 congestive heart failure, uncontrolled angina, uncontrolled hypertension, uncontrolled arrhythmia, myocardial infarction or stroke within 6 months of first protocol treatment or corrected QT (QTc) \> 480 ms